Citations (60)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Nizar N Zein. (2001) Experimental and emerging therapies for chronic hepatitis C virus infection. Expert Opinion on Investigational Drugs 10:8, pages 1457-1469.
Read now
Read now
Olle Reichard, Hand Glaumann & Ola Weiland. (1994) Long-term Histological Outcome in Patients with Chronic Hepatitis C Treated Repeatedly with Interferon alpha-2b without Sustained Response. Scandinavian Journal of Infectious Diseases 26:4, pages 383-389.
Read now
Read now
Ola Weiland & Robert Schvarcz. (1992) Hepatitis C: Virology, Epidemiology, Clinical Course, and Treatment. Scandinavian Journal of Gastroenterology 27:5, pages 337-342.
Read now
Read now
D. Bresters, E. P. Mauser-Bunschoten, H. T. M. Cuypers, P. N. Lelie, J. H. Han, P. L. M. Jansen, M. Houghton &H. W. Reesink. (1992) Disappearance of Hepatitis C Virus RNA in Plasma during Interferon Alpha-2B Treatment in Hemophilia Patients. Scandinavian Journal of Gastroenterology 27:3, pages 166-168.
Read now
Read now
Robert Schvarcz, Hans Glaumann, Ola Weiland, Gunnar Norkrans, Rune Wejstål & Aril Frydén. (1991) Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B/C hepatitis: Long-term outcome and effect of increased interferon doses in non-responders. Scandinavian Journal of Infectious Diseases 23:4, pages 413-420.
Read now
Read now
Olle Reichard & Jan Andersson. (1990) Ribavirin: A Possible Alternative for the Treatment of Chronic Non-A, Non-B Hepatitis. Scandinavian Journal of Infectious Diseases 22:4, pages 509-509.
Read now
Read now
Robert Schvarcz, Ola Weiland & Madeleine von Sydow. (1990) False Positive Reactivity for Antibodies against Hepatitis C Virus in Patients with Autoimmune Chronic Active Hepatitis?. Scandinavian Journal of Infectious Diseases 22:3, pages 377-378.
Read now
Read now
Articles from other publishers (53)
Izabella Jasyk & Jakub Siednienko. (2021) Type I interferon therapies of multiple sclerosis and hepatitis C virus infection. Postępy Higieny i Medycyny Doświadczalnej 75:1, pages 537-547.
Crossref
Crossref
Bianca Heinrich & John P. Bilello. 2017. Antimicrobial Drug Resistance. Antimicrobial Drug Resistance
579
609
.
Masahiko Nakayama, Hisanori Kobayashi, Koji Fukushima, Miwako Ishido, Yuji Komada & Kazutake Yoshizawa. (2015) Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin. Hepatology International 10:1, pages 158-168.
Crossref
Crossref
Markus von Schaewen, Qiang Ding & Alexander Ploss. (2014) Visualizing hepatitis C virus infection in humanized mice. Journal of Immunological Methods 410, pages 50-59.
Crossref
Crossref
R WEJSTÅL, G NORKRANS, O WEILAND, R SCHVARCZ, D FUCHS, H WACHTER, A FRYDEN & H GLAUMANN. (1992) Lymphocyte subsets and β2-microglobulin expression in chronic hepatitis C/non-A, non-B. Effects of interferon-alpha treatment. Clinical and Experimental Immunology 87:3, pages 340-345.
Crossref
Crossref
Fabio Tinè, Massimo Attanasio, Francesca Russo & Luigi Pagliaro. (2005) A decade of trials of interferon-alpha for chronic hepatitis C. A meta-regression analysis. Contemporary Clinical Trials 26:2, pages 179-210.
Crossref
Crossref
A K Jain, J Sukhija, J S Saini, Y Chawla & R K Dhiman. (2004) Hepatitis C virus-associated keratitis. Eye 18:2, pages 131-134.
Crossref
Crossref
Robert C Tam, Johnson YN Lau & Zhi Hong. (2016) Mechanisms of Action of Ribavirin in Antiviral Therapies. Antiviral Chemistry and Chemotherapy 12:5, pages 261-272.
Crossref
Crossref
Giuseppe Barbaro, Gabriella Di Lorenzo, Giancarlo Belloni, Luisella Ferrari, Aldo Paiano, Paolo Del Poggio, Donato Bacca, Luigi Fruttaldo, Franco Mongiò, Ruggiero Francavilla, Gaetano Scotto, Benvenuto Grisorio, Guido Calleri, Mauro Annese, Andrea Barelli, Piero Rocchetto, Giovanni Rizzo, Guido Gualandi, Italo Poltronieri & Giorgio Barbarini. (1999) Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial. The American Journal of Medicine 107:2, pages 112-118.
Crossref
Crossref
Peter Waldron. (1999) Interferon treatment of chronic active hepatitis C during therapy of acute lymphoblastic leukemia. American Journal of Hematology 61:2, pages 130-134.
Crossref
Crossref
Olle Reichard, Hans Glaumann, Aril Frydén, Gunnar Norkrans, Rune Wejstål & Ola Weiland. (1999) Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. Journal of Hepatology 30:5, pages 783-787.
Crossref
Crossref
S. GuerretA. DesmoulièreP. ChossegrosA. M. A. CostaC. BadidC. TrépoJ. A. Grimaud & M. Chevallier. (2002) Long‐term administration of interferon‐α in non‐responder patients with chronic hepatitis C: follow‐up of liver fibrosis over 5 years. Journal of Viral Hepatitis 6:2, pages 125-133.
Crossref
Crossref
Giuseppe Barbaro, Gabriella Di Lorenzo, Maurizio Soldini, Giuseppe Giancaspro, Giorgio Bellomo, Giancarlo Belloni, Benvenuto Grisorio, Mauro Annese, Donato Bacca, Ruggiero Francavilla, Giovanni Rizzo & Giorgio Barbarini. (1998) Interferon-α-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-α alone: an italian multicenter, randomized, controlled, clinical study. American Journal of Gastroenterology 93:12, pages 2445-2451.
Crossref
Crossref
Mariano Malaguarnera, Salvatore Restuccia, Massimo Motta, Pasqualina Ruello, Barbara A. Trovato & Giovanni Pistone. (2012) Interferon, Cortisone, and Antivirals in the Treatment of Chronic Viral Hepatitis: A Review of 30 Years of Therapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 17:5, pages 998-1005.
Crossref
Crossref
Dominik M. Alscher & J. Christian Bode. (1997) Therapie der Hepatitis C. Medizinische Klinik 92:3, pages 147-161.
Crossref
Crossref
Hidenori Toyoda, Takashi Kumada, Satoshi Nakano, Isao Takeda, Keiichi Sugiyama, Toshimasa Osada, Seiki Kiriyama, Yasuhiro Sone, Moritoshi Kinoshita & Toru Hadama. (1997) Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. Journal of Hepatology 26:1, pages 6-13.
Crossref
Crossref
Masao Arai, Maki Niioka, Katsuya Maruyama, Norihito Wada, Noboru Fujimoto, Tetsu Nomiyama, Shoutarou Tanaka & Isao Okazaki. (1996) Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon. Digestive Diseases and Sciences 41:5, pages 995-1000.
Crossref
Crossref
Gábor Horváth, Gyula Stotz, Gyula Tolvaj, Henrik Osztrogonácz & Károly Dávid. (1996) The effect of long term and high dose interferon treatment in Chronic hepatitis C. Pathology & Oncology Research 2:1-2, pages 59-62.
Crossref
Crossref
F. Bailly & C. Trepo. (1995) Traitement de l'hépatite virale C. Médecine et Maladies Infectieuses 25, pages 1097-1101.
Crossref
Crossref
H Toyoda, S Nakano, T Kumada, I Takeda, K Sugiyama, T Osada, S Kiriyama & M Takahashi. (2016) Treatment of Chronic Hepatitis C with Interferon-α: Sustained Absence of Hepatitis C Virus RNA from Serum after Four Courses of Therapy. Journal of International Medical Research 23:4, pages 308-314.
Crossref
Crossref
J. Enríquez, X. Torras, F. Miralles, F. J. Martinez Cerezo, F. J. Sancho Poch, J. Buenestado, P. Madoz, I. Howe & F. Vilardell. (2007) Comparative study of two high doses of lymphoblastoid interferon in the treatment of chronic hepatitis C: influence on the levels of ALT, viraemia and histologic activity. Journal of Viral Hepatitis 2:4, pages 181-187.
Crossref
Crossref
R. Schvarcz, Z. B. Yun, A. Sönnerborg & O. Weiland. (2005) Combined treatment with interferon alpha‐2b and ribavirin for chronic hepatitis C in patients with a previous non‐response or non‐sustained response to interferon alone. Journal of Medical Virology 46:1, pages 43-47.
Crossref
Crossref
Olle Reichard, Hans Glaumann, Aril Frydén, Gunnar Norkrans, Robert Schvarcz, Anders Sönnerborg, Zhi-Bing Yun & Ola Weiland. (1995) Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 21:4, pages 918-922.
Crossref
Crossref
A. Picciotto, F. Callea, G. Varagona, E. Bardellini, S. Borzone, V. De Conca, E. Vallarino, A. Giudici‐Cipriani, A. Vitali, A. Grasso, M. A. Palombino, M. Dodero, G. Marenco, G. Menardo & G. Celle. (2008) Lymphoblastoid interferon therapy in chronic hepatitis C: biochemical, virological and histological evaluation of two different doses. Liver 15:1, pages 20-24.
Crossref
Crossref
Eveline Boucher, Hervé Jouanolle, Patrice Andre, Annick Ruffault, Dominique Guyader, Romain Moirand, Bruno Turlin, Christian Jacquelinet, Pierre Brissot & Yves Deugnier. (1995) Interferon and ursodeoxycholic acid combined therapy in the treatmet of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients. Hepatology 21:2, pages 322-327.
Crossref
Crossref
Antonino Picciotto, Enrico Bardellini, Stefano Borzone, Nicoletta Sinelli, Antonio Giudici-Cipriani, Giuseppe Varagona, Alessandro Grasso, Maria Anna Palombino, Giorgio Marenco, Giorgio Menardo & Guido Celle. (1995) High-dose interferon therapy in patients with chronic hepatitis C: A biochemical and virologic evaluation. Current Therapeutic Research 56:1, pages 32-37.
Crossref
Crossref
Richard Cirelli & Stephen K. Tyring. (2012) Major Therapeutic Uses of Interferons. Clinical Immunotherapeutics 3:1, pages 27-87.
Crossref
Crossref
Olle Reichard, Hans Glauman, Gunnar Norkrans, Rune Wejstål, Aril Fryden, Robert Schvarcz & Ola Weiland. (2008) Histological outcome in patients with chronic hepatitis C given a 60‐week interferon alfa‐2b treatment course. Liver 14:4, pages 169-174.
Crossref
Crossref
Ola Weiland. (1994) Interferon therapy in chronic hepatitis C virus infection. FEMS Microbiology Reviews 14:3, pages 279-288.
Crossref
Crossref
Antonino Picciotto, Vincenzo Savarino, Enrico Bardellini, Stefano Borzone, Marinette Pireddu, Nicoletta Sinelli & Guido Celle. (1994) Effect of therapy with combined interferon and tauroursodeoxycholic acid in chronic hepatitis C: Biochemical and virologic evaluation. Current Therapeutic Research 55:6, pages 675-681.
Crossref
Crossref
Steven E. Wilson, William M. Lee, Carol Murakami, Jian Weng & George A. Moninger. (1994) Mooren-type Hepatitis C Virus-associated Corneal Ulceration. Ophthalmology 101:4, pages 736-745.
Crossref
Crossref
Olle Reichard, Ulla Foberg, Aril Frydén, Lars Mattsson, Gunnar Norkrans, Anders Sönnerborg, Rune Wejstål, Zhi-Bing Yun & Ola Weiland. (1994) High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α2b for 60 weeks. Hepatology 19:2, pages 280-285.
Crossref
Crossref
Paula Bonetti, Giulio Diodati, Claudio Drago, Carla Casarin, Sergio Scaccabarozzi, Giuseppe Realdi, Arturo Ruol & Alfredo Alberti. (1994) Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2α. Journal of Hepatology 20:3, pages 416-420.
Crossref
Crossref
Noboru Manabe, Michèle Chevallier, Philippe Chossegros, Xavier Causse, Sylviane Guerret, Christian Trépo & Jean-Alexis Grimaud. (1993) Interferon-α2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: A quantitative histological evaluation. Hepatology 18:6, pages 1344-1349.
Crossref
Crossref
Olle Reichard, Zhi‐Bing Yun, Anders Sönnerborg & Ola Weiland. (2005) Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. Journal of Medical Virology 41:2, pages 99-102.
Crossref
Crossref
David D. Douglas, Jorge Rakela, Hsiang Ju Lin, F. Blaine Hollinger, Howard F. Taswell, Albert J. Czaja, John B. Gross, Monte L. Anderson, Kevin Parent, C. Richard Fleming, John R. Cangemi, Peter C. O'Brien & Pauline E. Powis. (1993) Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Digestive Diseases and Sciences 38:4, pages 601-607.
Crossref
Crossref
Yun‐Fan Liaw, I‐Shyan Sheen, Shi‐Ming Lin, Tong‐Jong Chen & Chia‐Ming Chu. (2008) Effects of prednisolone pretreatment in interferon alfa therapy for patients with chronic non‐A, non‐B (C) hepatitis. Liver 13:1, pages 46-50.
Crossref
Crossref
Tatehiro Kagawa, Toshio Morizane, Hidetsugu Saito, Shingo Miyaguchi, Satoshi Tsunematsu, Shinichirou Tada, Ferdinand M. Guevara, Naoki Kumagai, Kanji Tsuchimoto, Tetsu Watanabe & Masaharu Tsuchiya. (1993) A randomized, controlled trial of weekly administration of lymphoblastoid interferon in patients with chronic hepatitis C. Journal of Hepatology 17:1, pages 91-96.
Crossref
Crossref
Joan Camps, Alberto Castilla, Juan Ruiz, María P. Civeira & Jesús Prieto. (1993) Randomised trial of lymphoblastoid α-interferon in chronic hepatitis C. Journal of Hepatology 17:3, pages 390-396.
Crossref
Crossref
A. Picciotto, G. Varagona, F. Valle, D.A. Coviello, G. Lapertosa & G. Celle. (1993) Interferon therapy in chronic hepatitis C. Journal of Hepatology 17:3, pages 359-363.
Crossref
Crossref
Rune Wejstàl, Gunnar Norkrans, Rodiça Lenkei, Ola Weiland, Robert Schvarcz & Aril Frydén. (2008) Peripheral blood lymphocyte subsets in patients with chronic hepatitis C – effects of interferon treatment. Liver 12:4, pages 161-167.
Crossref
Crossref
Lobna El-Ashmawy, Tarek Hassanein, Judith S. Gavaler & David H. Van Thiel. (1992) Prevalence of hepatitis C virus antibody in a liver transplantation population. Digestive Diseases and Sciences 37:7, pages 1110-1115.
Crossref
Crossref
Jonathan Brown, Spyros Dourakis, Peter Karayiannis, Robert Goldin, Joe Chiba, Hiroyoshi Ohba, Tatsuo Miyamura & Howard C. Thomas. (1992) Seroprevalence of hepatitis C virus nucleocapsid antibodies in patients with cryptogenic chronic liver disease. Hepatology 15:2, pages 175-179.
Crossref
Crossref
J. M. Sánchez-Tapias. 1992. Hepatobiliary Diseases. Hepatobiliary Diseases
573
609
.
Fabio Tine'Silvio Magrin, Antonio Craxi'Luigi Pagliaro. (1991) Interferon for non-A, non-B chronic hepatitis. Journal of Hepatology 13:2, pages 192-199.
Crossref
Crossref
Toshio Morizane, Tatehiro Kagawa, Hidetsugu Saito, Ferdinand M. Guevara, Shingo Miyaguchi & Masaharu Tsuchiya. (1991) Treatment of chronic hepatitis C with weekly administration of interferon-α. Gastroenterologia Japonica 26:S3, pages 254-255.
Crossref
Crossref
Yun-Fan Liaw, I-Shyan Sheen, Shi-Ming Lin & Tong-Jong Chen. (1991) Prednisolone withdrawal followed by recombinant alfainterferon in chronic non-A, non-B hepatitis: An interim results of a randomized controlled trial. Gastroenterologia Japonica 26:S3, pages 247-250.
Crossref
Crossref
Susan E. Gorman & Karen Plaisance. (2016) Application of Products Produced Through Biotechnology in Infectious Diseases. Journal of Pharmacy Practice 4:2, pages 103-116.
Crossref
Crossref
Toshio Ito, Kunihiko Sue, Takeshi Kakio, Mitsuru Muguruma, Takao Tsuji, Tadashi Teraoka, Sho Takeda, Masatoshi Hironaka, Kazuharu Murakami, Seigo Deguchi, Yasuo Namba & Sumihiro Hanahusa. (1991) Long-term intermittent administration of interferon-α in patients with chronic non-A, non-B hepatitis. Gastroenterologia Japonica 26:2, pages 187-193.
Crossref
Crossref
Robert Schvarcz, Hans Glaumann, Ola Weiland, Gunnar Norkrans, Rune Wejstål & Aril Frydén. (2008) Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis. Liver 11:1, pages 30-38.
Crossref
Crossref
G. Hess. 1991. Chronische Virushepatitis und ihre Behandlung mit Interferon alfa. Chronische Virushepatitis und ihre Behandlung mit Interferon alfa
76
85
.
C Haworth. (1990) Intron A — a therapeutic focus. International Journal of Clinical Practice 44:11, pages 471-474.
Crossref
Crossref
O. Weiland, R. Schvarcz, R. Wejstål, G. Norkrans & A. Frydén. (1990) Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience. Journal of Hepatology 11, pages S57-S62.
Crossref
Crossref